Your browser is no longer supported. Please, upgrade your browser.
iShares Evolved U.S. Innovative Healthcare ETF
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week2.13%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month4.07%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter13.08%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio- Perf Half Y9.58%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year20.66%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range21.69 - 34.11 Perf YTD4.97%
Dividend0.37 P/FCF- EPS past 5Y- ROI- 52W High-0.41% Beta-
Dividend %1.09% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low56.58% ATR0.42
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)75.72 Volatility1.05% 1.08%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.45 Prev Close33.97
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume10.42K Price33.97
Recom- SMA203.45% SMA507.05% SMA20014.11% Volume4,647 Change0.00%
Nov-19-20 04:00AM  
Oct-16-19 10:05AM  
Aug-27-19 10:05AM  
Jul-17-19 10:50AM  
Apr-17-19 10:35AM  
Mar-12-19 11:05AM  
Jan-23-19 10:59AM  
Jan-04-19 10:01AM  
Nov-26-18 11:15AM  
The investment seeks to provide access to U.S. companies with innovative healthcare exposure, as classified using a proprietary classification system. The fund invests, under normal circumstances, at least 80% of its net assets in U.S. listed common stock of large-, mid- and small-capitalization pharmaceutical and biotechnology companies. It will hold common stock of those companies that fall into the Innovative Healthcare Evolved Sector which have economic characteristics that have been historically correlated with companies traditionally defined as pharmaceutical and biotechnology companies. The fund is non-diversified.